Singapore markets closed

Roivant Sciences Ltd. (ROIV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.54-0.30 (-2.77%)
At close: 04:00PM EDT
10.53 -0.01 (-0.09%)
After hours: 05:28PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.84
Open10.81
Bid10.53 x 200
Ask10.55 x 7100
Day's range10.37 - 10.93
52-week range6.97 - 13.24
Volume64,414,422
Avg. volume5,710,893
Market cap8.494B
Beta (5Y monthly)1.37
PE ratio (TTM)2.00
EPS (TTM)5.27
Earnings date26 Jun 2024 - 01 Jul 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est16.08
  • PR Newswire

    Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

    Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions.

  • Simply Wall St.

    Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations

    Roivant Sciences ( NASDAQ:ROIV ) Third Quarter 2024 Results Key Financial Results Revenue: US$37.1m (up 118% from 3Q...

  • GlobeNewswire

    Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update

    BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a business update.Roivant completed the sale of Telavant to Roche for $7.1B with an additional $150M in cash payable upon the completion of a near-term milestoneBatoclimab produced positive results in Graves’ disease with response rates meaningfully exceeding 50% in the initial cohort of an ongoing 24